Founders Capital Management LLC Purchases 5,000 Shares of Amgen Inc. (NASDAQ:AMGN)

Founders Capital Management LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 32.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,348 shares of the medical research company’s stock after acquiring an additional 5,000 shares during the quarter. Amgen accounts for 1.2% of Founders Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. Founders Capital Management LLC’s holdings in Amgen were worth $5,861,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC grew its holdings in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after buying an additional 7,532,031 shares in the last quarter. Norges Bank purchased a new stake in Amgen during the 4th quarter valued at approximately $1,351,778,000. Price T Rowe Associates Inc. MD grew its holdings in Amgen by 158.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after buying an additional 1,806,456 shares in the last quarter. Morgan Stanley grew its holdings in Amgen by 12.9% during the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after buying an additional 1,523,665 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Amgen by 164.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,337,970 shares of the medical research company’s stock valued at $323,548,000 after buying an additional 832,885 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Raymond James assumed coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $286.00 to $326.00 in a research note on Tuesday, December 19th. UBS Group dropped their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $295.30.

Check Out Our Latest Analysis on Amgen

Amgen Stock Down 2.4 %

Amgen stock traded down $6.83 during trading hours on Tuesday, reaching $276.21. The stock had a trading volume of 2,220,460 shares, compared to its average volume of 3,009,285. The company has a market cap of $148.03 billion, a price-to-earnings ratio of 22.38, a PEG ratio of 2.69 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The business’s 50 day moving average price is $288.67 and its 200-day moving average price is $281.34. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.09 earnings per share. Sell-side analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.26%. Amgen’s dividend payout ratio is presently 72.06%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.